{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:41:11Z","timestamp":1787503271515,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosci. Bull."],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12264-025-01381-9","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T04:25:29Z","timestamp":1742444729000},"page":"1145-1160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oligodendrocyte Precursor Cell-Specific HMGB1 Knockout Reduces Immune Cell Infiltration and Demyelination in Experimental Autoimmune Encephalomyelitis Models"],"prefix":"10.1007","volume":"41","author":[{"given":"Gyuree","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiHye","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bokyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Jun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7106-1615","authenticated-orcid":false,"given":"Dong-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"1381_CR1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet 2008, 372: 1502\u20131517.","journal-title":"Lancet"},{"key":"1381_CR2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cen3.12591","volume":"11","author":"K Kimura","year":"2020","unstructured":"Kimura K. Regulatory T cells in multiple sclerosis. Clinical & Exp Neuroim 2020, 11: 148\u2013155.","journal-title":"Clinical & Exp Neuroim"},{"issue":"1-2","key":"1381_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0165-5728(93)90070-F","volume":"43","author":"MK Sharief","year":"1993","unstructured":"Sharief MK, Noori MA, Ciardi M, Cirelli A, Thompson EJ. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-\u03b1 and blood-brain barrier damage. J Neuroimmunol 1993, 43(1\u20132): 15\u201321. https:\/\/doi.org\/10.1016\/0165-5728(93)90070-F.","journal-title":"J Neuroimmunol"},{"key":"1381_CR4","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1093\/brain\/awac019","volume":"145","author":"H Nishihara","year":"2022","unstructured":"Nishihara H, Perriot S, Gastfriend BD, Steinfort M, Cibien C, Soldati S. Intrinsic blood-brain barrier dysfunction contributes to multiple sclerosis pathogenesis. Brain 2022, 145: 4334\u20134348.","journal-title":"Brain"},{"key":"1381_CR5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/biom12040538","volume":"12","author":"TG Schreiner","year":"2022","unstructured":"Schreiner TG, Romanescu C, Popescu BO. The blood-brain barrier-a key player in multiple sclerosis disease mechanisms. Biomolecules 2022, 12: 538.","journal-title":"Biomolecules"},{"key":"1381_CR6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010, 9: 883\u2013897.","journal-title":"Nat Rev Drug Discov"},{"key":"1381_CR7","first-page":"874","volume":"15","author":"L Aly","year":"2017","unstructured":"Aly L, Hemmer B, Korn T. From leflunomide to teriflunomide: Drug development and immunosuppressive oral drugs in the treatment of multiple sclerosis. Curr Neuropharmacol 2017, 15: 874\u2013891.","journal-title":"Curr Neuropharmacol"},{"key":"1381_CR8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: A phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2021, 20: 729\u2013738.","journal-title":"Lancet Neurol"},{"key":"1381_CR9","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.184.6.2271","volume":"184","author":"SD Wolf","year":"1996","unstructured":"Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996, 184: 2271\u20132278.","journal-title":"J Exp Med"},{"key":"1381_CR10","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.4049\/jimmunol.181.6.3750","volume":"181","author":"RA O\u2019Connor","year":"2008","unstructured":"O\u2019Connor RA, Prendergast CT, Sabatos CA, Lau CWZ, Leech MD, Wraith DC, et al. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2008, 181: 3750\u20133754.","journal-title":"J Immunol"},{"key":"1381_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04143.x","volume":"162","author":"JM Fletcher","year":"2010","unstructured":"Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KG. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010, 162: 1\u201311.","journal-title":"Clin Exp Immunol"},{"key":"1381_CR12","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1172\/JCI130308","volume":"130","author":"Z Li","year":"2020","unstructured":"Li Z, Korhonen EA, Merlini A, Strauss J, Wihuri E, Nurmi H, et al. Angiopoietin-2 blockade ameliorates autoimmune neuroinflammation by inhibiting leukocyte recruitment into the CNS. J Clin Invest 2020, 130: 1977\u20131990.","journal-title":"J Clin Invest"},{"key":"1381_CR13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.expneurol.2014.05.013","volume":"261","author":"H Jiang","year":"2014","unstructured":"Jiang H, Zhang F, Yang J, Han S. Angiopoietin-1 ameliorates inflammation-induced vascular leakage and improves functional impairment in a rat model of acute experimental autoimmune encephalomyelitis. Exp Neurol 2014, 261: 245\u2013257.","journal-title":"Exp Neurol"},{"key":"1381_CR14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jneuroim.2010.08.011","volume":"229","author":"J Bennett","year":"2010","unstructured":"Bennett J, Basivireddy J, Kollar A, Biron KE, Reickmann P, Jefferies WA, et al. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J Neuroimmunol 2010, 229: 180\u2013191.","journal-title":"J Neuroimmunol"},{"key":"1381_CR15","doi-asserted-by":"crossref","first-page":"116924","DOI":"10.1016\/j.lfs.2019.116924","volume":"238","author":"YN Paudel","year":"2019","unstructured":"Paudel YN, Angelopoulou E, Bhuvan CK, Piperi C, Othman I. High mobility group box 1 (HMGB1) protein in multiple sclerosis (MS): mechanisms and therapeutic potential. Life Sci 2019, 238: 116924.","journal-title":"Life Sci"},{"key":"1381_CR16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10072-019-04136-3","volume":"41","author":"M Bucova","year":"2020","unstructured":"Bucova M, Majernikova B, Durmanova V, Cudrakova D, Gmitterova K, Lisa I, et al. HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis. Neurol Sci 2020, 41: 599\u2013604.","journal-title":"Neurol Sci"},{"key":"1381_CR17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","volume":"54","author":"R Chen","year":"2022","unstructured":"Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. Exp Mol Med 2022, 54: 91\u2013102.","journal-title":"Exp Mol Med"},{"key":"1381_CR18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrrheum.2011.222","volume":"8","author":"HE Harris","year":"2012","unstructured":"Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012, 8: 195\u2013202.","journal-title":"Nat Rev Rheumatol"},{"key":"1381_CR19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/01.shk.0000225404.51320.82","volume":"26","author":"M Yu","year":"2006","unstructured":"Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26: 174\u2013179.","journal-title":"Shock"},{"key":"1381_CR20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2119\/molmed.2013.00164","volume":"20","author":"M Magna","year":"2014","unstructured":"Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol Med 2014, 20: 138\u2013146.","journal-title":"Mol Med"},{"key":"1381_CR21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s10020-023-00717-3","volume":"29","author":"W Ren","year":"2023","unstructured":"Ren W, Zhao L, Sun Y, Wang X, Shi X. HMGB1 and toll-like receptors: Potential therapeutic targets in autoimmune diseases. Mol Med 2023, 29: 117.","journal-title":"Mol Med"},{"key":"1381_CR22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12974-015-0269-9","volume":"12","author":"S Malhotra","year":"2015","unstructured":"Malhotra S, Fissolo N, Tintor\u00e9 M, Wing AC, Castill\u00f3 J, Vidal-Jordana A, et al. Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. J Neuroinflammation 2015, 12: 48.","journal-title":"J Neuroinflammation"},{"key":"1381_CR23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jaut.2013.02.005","volume":"43","author":"AP Robinson","year":"2013","unstructured":"Robinson AP, Caldis MW, Harp CT, Goings GE, Miller SD. High-mobility group box 1 protein (HMGB1) neutralization ameliorates experimental autoimmune encephalomyelitis. J Autoimmun 2013, 43: 32\u201343.","journal-title":"J Autoimmun"},{"key":"1381_CR24","volume":"161","author":"J Mo","year":"2023","unstructured":"Mo J, Hu J, Cheng X. The role of high mobility group box 1 in neuroinflammatory related diseases. Biomed Pharmacother 2023, 161: 114541.","journal-title":"Biomed Pharmacother"},{"key":"1381_CR25","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s12264-022-00890-1","volume":"38","author":"J Shi","year":"2022","unstructured":"Shi J, Xiao Y, Zhang N, Jiao M, Tang X, Dai C, et al. HMGB1 from astrocytes promotes EAE by influencing the immune cell infiltration-associated functions of BMECs in mice. Neurosci Bull 2022, 38: 1303\u20131314.","journal-title":"Neurosci Bull"},{"key":"1381_CR26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jneuroim.2015.02.005","volume":"280","author":"Y Sun","year":"2015","unstructured":"Sun Y, Chen H, Dai J, Zou H, Gao M, Wu H, et al. HMGB1 expression patterns during the progression of experimental autoimmune encephalomyelitis. J Neuroimmunol 2015, 280: 29\u201335.","journal-title":"J Neuroimmunol"},{"key":"1381_CR27","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3389\/fimmu.2018.01518","volume":"9","author":"Y Sun","year":"2018","unstructured":"Sun Y, Chen H, Dai J, Wan Z, Xiong P, Xu Y, et al. Glycyrrhizin protects mice against experimental autoimmune encephalomyelitis by inhibiting high-mobility group box 1 (HMGB1) expression and neuronal HMGB1 release. Front Immunol 2018, 9: 1518.","journal-title":"Front Immunol"},{"key":"1381_CR28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tins.2019.01.002","volume":"42","author":"B Elbaz","year":"2019","unstructured":"Elbaz B, Popko B. Molecular control of oligodendrocyte development. Trends Neurosci 2019, 42: 263\u2013277.","journal-title":"Trends Neurosci"},{"key":"1381_CR29","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3390\/cells8111424","volume":"8","author":"S Kuhn","year":"2019","unstructured":"Kuhn S, Gritti L, Crooks D, Dombrowski Y. Oligodendrocytes in development, myelin generation and beyond. Cells 2019, 8: 1424.","journal-title":"Cells"},{"key":"1381_CR30","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134601","volume":"715","author":"EP Harrington","year":"2020","unstructured":"Harrington EP, Bergles DE, Calabresi PA. Immune cell modulation of oligodendrocyte lineage cells. Neurosci Lett 2020, 715: 134601.","journal-title":"Neurosci Lett"},{"key":"1381_CR31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41593-019-0369-4","volume":"22","author":"J Niu","year":"2019","unstructured":"Niu J, Tsai HH, Hoi KK, Huang N, Yu G, Kim K, et al. Aberrant oligodendroglial-vascular interactions disrupt the blood-brain barrier, triggering CNS inflammation. Nat Neurosci 2019, 22: 709\u2013718.","journal-title":"Nat Neurosci"},{"key":"1381_CR32","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1038\/s41467-019-11638-3","volume":"10","author":"L Kirby","year":"2019","unstructured":"Kirby L, Jin J, Cardona JG, Smith MD, Martin KA, Wang J, et al. Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination. Nat Commun 2019, 10: 3887.","journal-title":"Nat Commun"},{"key":"1381_CR33","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41591-018-0236-y","volume":"24","author":"AM Falc\u00e3o","year":"2018","unstructured":"Falc\u00e3o AM, van Bruggen D, Marques S, Meijer M, J\u00e4kel S, Agirre E, et al. Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. Nat Med 2018, 24: 1837\u20131844.","journal-title":"Nat Med"},{"key":"1381_CR34","doi-asserted-by":"publisher","DOI":"10.3791\/51275","author":"S Bittner","year":"2014","unstructured":"Bittner S, Afzali AM, Wiendl H, Meuth SG. Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL\/6 mice. J Vis Exp 2014, https:\/\/doi.org\/10.3791\/51275.","journal-title":"J Vis Exp"},{"key":"1381_CR35","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/nprot.2007.149","volume":"2","author":"Y Chen","year":"2007","unstructured":"Chen Y, Balasubramaniyan V, Peng J, Hurlock EC, Tallquist M, Li J, et al. Isolation and culture of rat and mouse oligodendrocyte precursor cells. Nat Protoc 2007, 2: 1044\u20131051.","journal-title":"Nat Protoc"},{"key":"1381_CR36","volume":"19","author":"C Schoor","year":"2019","unstructured":"Schoor C, Brocke-Ahmadinejad N, Gieselmann V, Winter D. Investigation of oligodendrocyte precursor cell differentiation by quantitative proteomics. Proteomics 2019, 19: e1900057.","journal-title":"Proteomics"},{"key":"1381_CR37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-1-0716-3052-5_22","volume":"2644","author":"CR Justus","year":"2023","unstructured":"Justus CR, Marie MA, Sanderlin EJ, Yang LV. Transwell in vitro cell migration and invasion assays. Methods Mol Biol 2023, 2644: 349\u2013359.","journal-title":"Methods Mol Biol"},{"key":"1381_CR38","doi-asserted-by":"crossref","first-page":"18071","DOI":"10.1038\/s41598-017-14716-y","volume":"7","author":"V van Duinen","year":"2017","unstructured":"van Duinen V, van den Heuvel A, Trietsch SJ, Lanz HL, van Gils JM, van Zonneveld AJ, et al. 96 perfusable blood vessels to study vascular permeability in vitro. Sci Rep 2017, 7: 18071.","journal-title":"Sci Rep"},{"key":"1381_CR39","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1038\/s41467-019-13812-z","volume":"10","author":"K Haruwaka","year":"2019","unstructured":"Haruwaka K, Ikegami A, Tachibana Y, Ohno N, Konishi H, Hashimoto A, et al. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat Commun 2019, 10: 5816.","journal-title":"Nat Commun"},{"key":"1381_CR40","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00418-019-01768-6","volume":"151","author":"L Bell","year":"2019","unstructured":"Bell L, Koeniger T, Tacke S, Kuerten S. Characterization of blood-brain barrier integrity in a B-cell-dependent mouse model of multiple sclerosis. Histochem Cell Biol 2019, 151: 489\u2013499.","journal-title":"Histochem Cell Biol"},{"key":"1381_CR41","doi-asserted-by":"crossref","first-page":"19194","DOI":"10.1038\/s41598-019-55713-7","volume":"9","author":"SK Shahi","year":"2019","unstructured":"Shahi SK, Freedman SN, Dahl RA, Karandikar NJ, Mangalam AK. Scoring disease in an animal model of multiple sclerosis using a novel infrared-based automated activity-monitoring system. Sci Rep 2019, 9: 19194.","journal-title":"Sci Rep"},{"key":"1381_CR42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/imm.13047","volume":"157","author":"FE Vel\u00e1zquez","year":"2019","unstructured":"Vel\u00e1zquez FE, Anastasiou M, Carrillo-Salinas FJ, Ngwenyama N, Salvador AM, Nevers T, et al. Sialomucin CD43 regulates T helper type 17 cell intercellular adhesion molecule 1 dependent adhesion, apical migration and transendothelial migration. Immunology 2019, 157: 52\u201369.","journal-title":"Immunology"},{"key":"1381_CR43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbi.2018.06.014","volume":"73","author":"S Tietz","year":"2018","unstructured":"Tietz S, P\u00e9rinat T, Greene G, Enzmann G, Deutsch U, Adams R, et al. Lack of junctional adhesion molecule (JAM)-B ameliorates experimental autoimmune encephalomyelitis. Brain Behav Immun 2018, 73: 3\u201320.","journal-title":"Brain Behav Immun"},{"key":"1381_CR44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/toxsci\/kfp274","volume":"114","author":"DA Johnson","year":"2010","unstructured":"Johnson DA, Amirahmadi S, Ward C, Fabry Z, Johnson JA. The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicol Sci 2010, 114: 237\u2013246.","journal-title":"Toxicol Sci"},{"key":"1381_CR45","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1523\/JNEUROSCI.2477-13.2014","volume":"34","author":"DE Harlow","year":"2014","unstructured":"Harlow DE, Saul KE, Culp CM, Vesely EM, Macklin WB. Expression of proteolipid protein gene in spinal cord stem cells and early oligodendrocyte progenitor cells is dispensable for normal cell migration and myelination. J Neurosci 2014, 34: 1333\u20131343.","journal-title":"J Neurosci"},{"key":"1381_CR46","doi-asserted-by":"crossref","first-page":"12921","DOI":"10.1038\/s41598-022-17081-7","volume":"12","author":"RM Beiter","year":"2022","unstructured":"Beiter RM, Rivet-Noor C, Merchak AR, Bai R, Johanson DM, Slogar E, et al. Evidence for oligodendrocyte progenitor cell heterogeneity in the adult mouse brain. Sci Rep 2022, 12: 12921.","journal-title":"Sci Rep"},{"key":"1381_CR47","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101728","volume":"3","author":"Y Harada","year":"2022","unstructured":"Harada Y, Miyamoto K, Sujino T. Protocol to isolate and enrich mouse splenic naive CD4+ T cells for in vitro CD4+CD8\u03b1\u03b1+ cell induction. STAR Protoc 2022, 3: 101728.","journal-title":"STAR Protoc"},{"key":"1381_CR48","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1084\/jem.20111739","volume":"209","author":"M Schiraldi","year":"2012","unstructured":"Schiraldi M, Raucci A, Mu\u00f1oz LM, Livoti E, Celona B, Venereau E, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012, 209: 551\u2013563.","journal-title":"J Exp Med"},{"key":"1381_CR49","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.3390\/cells9122650","volume":"9","author":"M Nishibori","year":"2020","unstructured":"Nishibori M, Wang D, Ousaka D, Wake H. High mobility group box-1 and blood-brain barrier disruption. Cells 2020, 9: 2650.","journal-title":"Cells"},{"key":"1381_CR50","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/STROKEAHA.122.041414","volume":"54","author":"JY Choi","year":"2023","unstructured":"Choi JY, Jin X, Kim H, Koh S, Cho HJ, Kim BG. High mobility group box 1 as an autocrine chemoattractant for oligodendrocyte lineage cells in white matter stroke. Stroke 2023, 54: 575\u2013586.","journal-title":"Stroke"},{"key":"1381_CR51","doi-asserted-by":"crossref","first-page":"E4987","DOI":"10.1073\/pnas.1621447114","volume":"114","author":"JY Choi","year":"2017","unstructured":"Choi JY, Cui Y, Chowdhury ST, Kim BG. High-mobility group box-1 as an autocrine trophic factor in white matter stroke. Proc Natl Acad Sci U S A 2017, 114: E4987\u2013E4995.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1381_CR52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1242\/jcs.176412","volume":"129","author":"YH Kim","year":"2016","unstructured":"Kim YH, Kwak MS, Park JB, Lee SA, Choi JE, Cho HS, et al. N-linked glycosylation plays a crucial role in the secretion of HMGB1. J Cell Sci 2016, 129: 29\u201338.","journal-title":"J Cell Sci"},{"key":"1381_CR53","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1073\/pnas.1316925111","volume":"111","author":"B Lu","year":"2014","unstructured":"Lu B, Antoine DJ, Kwan K, Lundb\u00e4ck P, W\u00e4h\u00e4maa H, Schierbeck H, et al. JAK\/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci USA 2014, 111: 3068\u20133073.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1381_CR54","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s12012-020-09571-9","volume":"20","author":"SY Ni","year":"2020","unstructured":"Ni SY, Zhong XL, Li ZH, Huang DJ, Xu WT, Zhou Y, et al. Puerarin alleviates lipopolysaccharide-induced myocardial fibrosis by inhibiting PARP-1 to prevent HMGB1-mediated TLR4-NF-\u03baB signaling pathway. Cardiovasc Toxicol 2020, 20: 482\u2013491.","journal-title":"Cardiovasc Toxicol"},{"key":"1381_CR55","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3389\/fimmu.2020.01189","volume":"11","author":"MS Kwak","year":"2020","unstructured":"Kwak MS, Kim HS, Lee B, Kim YH, Son M, Shin JS. Immunological significance of HMGB1 post-translational modification and redox biology. Front Immunol 2020, 11: 1189.","journal-title":"Front Immunol"},{"key":"1381_CR56","volume":"24","author":"MS Kwak","year":"2019","unstructured":"Kwak MS, Kim HS, Lkhamsuren K, Kim YH, Han MG, Shin JM, et al. Peroxiredoxin-mediated disulfide bond formation is required for nucleocytoplasmic translocation and secretion of HMGB1 in response to inflammatory stimuli. Redox Biol 2019, 24: 101203.","journal-title":"Redox Biol"}],"container-title":["Neuroscience Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-025-01381-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12264-025-01381-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-025-01381-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:34:58Z","timestamp":1751517298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12264-025-01381-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1007\/s12264-025-01381-9","relation":{},"ISSN":["1673-7067","1995-8218"],"issn-type":[{"value":"1673-7067","type":"print"},{"value":"1995-8218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"25 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}